Correlation Between Pentair PLC and Mineralys Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Pentair PLC and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pentair PLC and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pentair PLC and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Pentair PLC and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pentair PLC with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pentair PLC and Mineralys Therapeutics,.

Diversification Opportunities for Pentair PLC and Mineralys Therapeutics,

-0.24

Correlation Coefficient

Pentair PLC  Mineralys Therapeutics,

Very good diversification

The 3 months correlation between Pentair and Mineralys is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding Pentair PLC and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Pentair PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pentair PLC are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Pentair PLC i.e., Pentair PLC and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Pentair PLC and Mineralys Therapeutics,

Considering the 90-day investment horizon Pentair PLC is expected to under-perform the Mineralys Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Pentair PLC is 3.4 times less risky than Mineralys Therapeutics,. The stock trades about -0.26 of its potential returns per unit of risk. The Mineralys Therapeutics, Common is currently generating about -0.05 of returns per unit of risk over similar time horizon. If you would invest  1,311  in Mineralys Therapeutics, Common on September 28, 2024 and sell it today you would lose (68.00) from holding Mineralys Therapeutics, Common or give up 5.19% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Pentair PLC  vs.  Mineralys Therapeutics, Common

Pentair PLC

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Pentair PLC are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable basic indicators, Pentair PLC is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

Mineralys Therapeutics,

Risk-Adjusted Performance

2 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Pentair PLC and Mineralys Therapeutics,

The main advantage of trading using opposite Pentair PLC and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pentair PLC position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.

The idea behind Pentair PLC and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.